Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2021-08-26 AGM Information
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Annual General Meeting 2 pages 156.8KB
AGM Information Classification · 95% confidence The document is a notice announcing the scheduling of the company's 2021 Annual General Meeting (AGM), including details about the date, business items such as director re-election, and nomination deadlines. It references compliance with ASX Listing Rule 3.13.1 and provides contact information and company background. There is no detailed financial data, management discussion, or full report content. The document is short (3832 characters) and serves as an announcement rather than the actual AGM materials or minutes. Therefore, it fits the category of AGM Information (AGM-R).
2021-08-26 English
Appendix 4G 13 pages 312.4KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed form used to confirm compliance with corporate governance disclosure requirements as part of the annual report filing process. The document includes a key to where governance disclosures can be found, and it is explicitly stated that Appendix 4G is lodged with the annual report but is not a substitute for the corporate governance statement itself. The content focuses on governance principles, board charters, diversity policies, and evaluation processes, which aligns with governance information rather than a full annual report or other financial filings. The document is not a full annual report but a regulatory compliance filing related to governance disclosures. Therefore, the most appropriate classification is Governance Information (CGR).
2021-08-26 English
Appendix 4E and Annual Report to Shareholders 66 pages 4.5MB
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E Preliminary final Report' and includes detailed financial data for the year ended 30 June 2021. It contains comprehensive sections such as Directors' Report, Auditor's independence declaration, consolidated financial statements, notes to the financial statements, directors' declaration, independent auditor's report, and corporate governance statement. The presence of full financial statements and detailed management discussion indicates this is a full annual report. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K equivalent). FY 2021
2021-08-26 English
CelGro Nerve Study Results Presented at AOA annual Meeting 3 pages 251.7KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the successful results of a clinical and pre-clinical study on the CelGro® nerve repair product. It details study outcomes, clinical significance, and next steps including regulatory and commercial plans. There are no financial statements, regulatory certifications, or detailed financial data. The document is not a full financial report, audit, or earnings release. It is a corporate announcement focused on clinical trial results and product development progress, typical of a Capital/Financing Update or general corporate update. Given the focus on study results and commercial/regulatory milestones, the best fitting category is Capital/Financing Update (CAP). The document length (9292 characters) and content do not indicate it is a report publication announcement or regulatory filing. Confidence is high due to clear clinical study result announcement and commercial progress update.
2021-08-22 English
Application for quotation of securities - OCC 6 pages 27.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This is a formal announcement related to capital changes, specifically the issuance and quotation of new shares following option exercises. It does not contain financial statements, management discussion, or audit information. Therefore, it fits the category of Share Issue/Capital Change announcements.
2021-08-18 English
Notice under Section 708(A) of the Corporations Act 2 pages 152.3KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act, which relates to the issuance of securities without disclosure under Part 6D.2 of the Corporations Act. It provides details about the securities issued, compliance statements, and confirms no excluded information exists that would affect investor decisions. The document is short (3161 characters) and serves as a formal announcement of a capital raising event without detailed financial data or analysis. It is not a full financial report, earnings release, or management discussion. This fits the definition of a Capital/Financing Update (CAP) as it updates on company fundraising and capital structure changes.
2021-08-18 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.